? Core C The aims of the Neuropathology Core are: ? to provide a high-quality, comprehensive and standardized neuropathological service to research groups in the program, ? to provide advice and expertise on neuropathological interpretation to research groups in the ? program, ? to record histopathological findings and assessments in a form that is both accessible to the ? research groups in the program and readily integrated with other data for the purposes of ? comparative analysis, ? to develop the classification of mouse model and human central nervous system (CNS) tumors established in programmatic studies to date. A uniform approach to histological analysis is essential to this research program. High-quality histologic methodologies and expert evaluation of preparations will enable a robust and detailed characterization of human and mouse CNS tumors from across the program. There is scope for a detailed comparative analysis at histological and molecular levels of human and mouse model CNS tumors, both within one histopathological category, e.g. astrocytic versus oligodendroglial tumors among the high-grade gliomas, and across categories, e.g. gliomas versus embryonal tumors, such as the primitive neuroectodermal tumor. Histopathological analysis will be critical across programmatic research studies in order to study the effects of genotype on CNS development, to characterize neoplastic events, to determine molecular cytogenetic alterations at the individual cell level, and to evaluate the effects of therapeutics on neoplasms and normal CNS.
? Core C An increased understanding of the biology of childhood brain tumors will advance treatment of these devastating diseases. Mouse models accurately replicating their pathologies can be used to determine how critical genetic alterations drive neoplastic growth and how therapeutic agents might target oncogenesis. Core C will play a central role in evaluating characteristics of mouse models and any therapeutic effects.
| Pajtler, Kristian W; Wen, Ji; Sill, Martin et al. (2018) Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathol 136:211-226 |
| Teitz, Tal; Fang, Jie; Goktug, Asli N et al. (2018) CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss. J Exp Med 215:1187-1203 |
| Tsang, Derek S; Burghen, Elizabeth; Klimo Jr., Paul et al. (2018) Outcomes After Reirradiation for Recurrent Pediatric Intracranial Ependymoma. Int J Radiat Oncol Biol Phys 100:507-515 |
| Shadrick, William R; Slavish, Peter J; Chai, Sergio C et al. (2018) Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors. Bioorg Med Chem 26:25-36 |
| Roussel, Martine F; Stripay, Jennifer L (2018) Epigenetic Drivers in Pediatric Medulloblastoma. Cerebellum 17:28-36 |
| Waszak, Sebastian M; Northcott, Paul A; Buchhalter, Ivo et al. (2018) Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol 19:785-798 |
| El Nagar, Salsabiel; Zindy, Frederique; Moens, Charlotte et al. (2018) A new genetically engineered mouse model of choroid plexus carcinoma. Biochem Biophys Res Commun 496:568-574 |
| Nimmervoll, Birgit V; Boulos, Nidal; Bianski, Brandon et al. (2018) Establishing a Preclinical Multidisciplinary Board for Brain Tumors. Clin Cancer Res 24:1654-1666 |
| Vo, BaoHan T; Kwon, Jin Ah; Li, Chunliang et al. (2018) Mouse medulloblastoma driven by CRISPR activation of cellular Myc. Sci Rep 8:8733 |
| Hoch, Nicolas C; Hanzlikova, Hana; Rulten, Stuart L et al. (2017) XRCC1 mutation is associated with PARP1 hyperactivation and cerebellar ataxia. Nature 541:87-91 |
Showing the most recent 10 out of 208 publications
